The 43 months survival is from a dose escalation study. That survival was calculated - and it involved only those who had the higher doe of that treatment.
The full text paper is available at: Phase1/2 study of fractionated dose lutetium‐177–labeledanti–prostate‐specific membrane antigenmonoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistantprostate cancer - Tagawa - 2019 - Cancer - Wiley Online Library
Ann: Clarity to present COBRA and CLARIFY abstracts, page-70
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$4.11 |
Change
-0.200(4.64%) |
Mkt cap ! $1.329B | |||
| Open | High | Low | Value | Volume |
| $4.20 | $4.27 | $4.09 | $7.447M | 1.792M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $4.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.12 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| CU6 (ASX) Chart |